tiprankstipranks
Advertisement
Advertisement
Voyager Therapeutics reports Q1 EPS (47c), consensus (53c)
PremiumThe FlyVoyager Therapeutics reports Q1 EPS (47c), consensus (53c)
20d ago
Voyager Therapeutics management to meet with Oppenheimer
Premium
The Fly
Voyager Therapeutics management to meet with Oppenheimer
30d ago
Voyager Therapeutics Announces CFO Resignation and Finance Leadership Changes
Premium
Company Announcements
Voyager Therapeutics Announces CFO Resignation and Finance Leadership Changes
1M ago
Voyager Therapeutics: Advancing Tau-Targeted Gene Therapy with Multiple Near-Term Catalysts and Attractive Risk-Reward
PremiumRatingsVoyager Therapeutics: Advancing Tau-Targeted Gene Therapy with Multiple Near-Term Catalysts and Attractive Risk-Reward
3M ago
Voyager Therapeutics Faces Rising Tariff and U.S.–China Geopolitical Risks as BIOSECURE Act Threatens Key Chinese CDMO Partnerships
Premium
Company Announcements
Voyager Therapeutics Faces Rising Tariff and U.S.–China Geopolitical Risks as BIOSECURE Act Threatens Key Chinese CDMO Partnerships
3M ago
Voyager Therapeutics: Undervalued Neurology Pipeline With High-Reward 2026 Catalysts Supports Buy Rating
Premium
Ratings
Voyager Therapeutics: Undervalued Neurology Pipeline With High-Reward 2026 Catalysts Supports Buy Rating
3M ago
Voyager Therapeutics Highlights 2026 CNS Pipeline and Strategy
PremiumCompany AnnouncementsVoyager Therapeutics Highlights 2026 CNS Pipeline and Strategy
5M ago
Voyager Therapeutics price target lowered to $25 from $30 at H.C. Wainwright
Premium
The Fly
Voyager Therapeutics price target lowered to $25 from $30 at H.C. Wainwright
7M ago
Voyager Therapeutics Reports Increased Losses Amid Rising R&D Costs
Premium
Company Announcements
Voyager Therapeutics Reports Increased Losses Amid Rising R&D Costs
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100